SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NutraLife BioSciences, Inc. (NLBS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NLBS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-0.11 |
$597.78K |
$-2.08M |
-348.5% |
| 2014 |
$-0.10 |
$62.27K |
$-2.08M |
-3333.2% |
| 2015 |
$-0.09 |
$194K |
$-2.1M |
-1083% |
| 2016 |
$-0.06 |
$225.29K |
$-2.1M |
-931.6% |
| 2017 |
$-0.33 |
$1.79M |
$-23.63M |
-1319.9% |
| 2018 |
$-0.02 |
$3.71M |
$-2.07M |
-55.9% |
| 2019 |
$-0.04 |
$2.13M |
$-4.01M |
-187.8% |
| 2020 |
$-0.02 |
$1.26M |
$-2.89M |
-230.1% |
| 2021 |
$-0.04 |
$626.62K |
$-5.83M |
-930% |
| 2022 |
$0.00 |
$0.00 |
$0.00 |
- |
